• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

功能与分子影像学：在局限性前列腺癌的诊断与分期中的应用。

Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer.

机构信息

Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1088, USA.

出版信息

Clin Oncol (R Coll Radiol). 2013 Aug;25(8):451-60. doi: 10.1016/j.clon.2013.05.001. Epub 2013 May 27.

DOI:10.1016/j.clon.2013.05.001
PMID:23722008
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6330112/
Abstract

Prostate cancer is currently the most common solid organ cancer type among men in the Western world. Currently, all decision-making algorithms and nomograms rely on demographics, clinicopathological data and symptoms. Such an approach can easily miss significant cancers while detecting many insignificant cancers. In this review, novel functional and molecular imaging techniques used in the diagnosis and staging of localised prostate cancer and their effect on treatment decisions are discussed.

摘要

目前，前列腺癌是西方世界男性中最常见的实体器官癌症类型。目前，所有的决策算法和诺莫图都依赖于人口统计学、临床病理数据和症状。这种方法很容易错过重要的癌症，同时检测到许多不重要的癌症。在这篇综述中，讨论了用于诊断和分期局限性前列腺癌的新型功能和分子成像技术及其对治疗决策的影响。

相似文献

1
Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer.功能与分子影像学：在局限性前列腺癌的诊断与分期中的应用。
Clin Oncol (R Coll Radiol). 2013 Aug;25(8):451-60. doi: 10.1016/j.clon.2013.05.001. Epub 2013 May 27.
2
Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.分子成像在前列腺癌管理中的临床应用
PET Clin. 2017 Apr;12(2):185-192. doi: 10.1016/j.cpet.2016.11.001. Epub 2017 Jan 16.
3
Molecular Imaging for Primary Staging of Prostate Cancer.用于前列腺癌初始分期的分子影像学。
Semin Nucl Med. 2019 Jul;49(4):271-279. doi: 10.1053/j.semnuclmed.2019.02.004. Epub 2019 Mar 20.
4
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
5
[Place of molecular imaging in the management of prostate cancer].[分子成像在前列腺癌管理中的地位]
Cancer Radiother. 2021 Oct;25(6-7):663-666. doi: 10.1016/j.canrad.2021.07.032. Epub 2021 Aug 14.
6
Molecular Imaging of Newly Diagnosed Prostate Cancer.新发前列腺癌的分子影像学
Cancer J. 2020 Jan/Feb;26(1):43-47. doi: 10.1097/PPO.0000000000000427.
7
The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.前列腺癌分期的植物学未来：PSMA-PET 和蒲公英理论。
Future Oncol. 2017 Aug;13(20):1801-1807. doi: 10.2217/fon-2017-0074. Epub 2017 Aug 1.
8
[Molecular multimodal hybrid imaging in prostate and bladder cancer].[前列腺癌和膀胱癌的分子多模态混合成像]
Urologe A. 2014 Apr;53(4):469-83. doi: 10.1007/s00120-014-3440-5.
9
Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers: An Overview.乳腺癌和前列腺癌骨转移的分子和功能影像学：概述。
Clin Nucl Med. 2016 Jan;41(1):e44-50. doi: 10.1097/RLU.0000000000000993.
10
Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancer.泌尿科诊断检测：前列腺癌分期的磁共振成像（MRI）。
BJU Int. 2013 Mar;111(3):514-7. doi: 10.1111/j.1464-410X.2012.11447.x. Epub 2013 Jan 15.

引用本文的文献

1
Dynamic Contrast Enhanced Study in Multiparametric Examination of the Prostate-Can We Make Better Use of It?动态对比增强研究在前列腺多参数检查中的应用——我们能否更好地利用它？
Tomography. 2022 Jun 9;8(3):1509-1521. doi: 10.3390/tomography8030124.
2
Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.外显肽 B 型纤连蛋白靶向肽 Gd-DOTA 轭合物的合成与评价及其在前列腺癌磁共振分子成像中的应用
Mol Pharm. 2017 Nov 6;14(11):3906-3915. doi: 10.1021/acs.molpharmaceut.7b00619. Epub 2017 Oct 25.
3
Ultrasound Elastography of the Prostate Using an Unconstrained Modulus Reconstruction Technique: A Pilot Clinical Study.使用无约束模量重建技术的前列腺超声弹性成像：一项初步临床研究。
Transl Oncol. 2017 Oct;10(5):744-751. doi: 10.1016/j.tranon.2017.06.006. Epub 2017 Jul 20.
4
DCE MRI of prostate cancer.前列腺癌的 DCE-MRI 研究。
Abdom Radiol (NY). 2016 May;41(5):844-53. doi: 10.1007/s00261-015-0589-3.
5
Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.使用抗3-[(18)F]FACBC PET/CT检测复发性前列腺癌：与CT的比较。
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18.
6
Prognostic Utility of PET in Prostate Cancer.正电子发射断层扫描（PET）在前列腺癌中的预后效用
PET Clin. 2015 Apr;10(2):255-63. doi: 10.1016/j.cpet.2014.12.007. Epub 2015 Jan 22.
7
Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patients.定量超声光谱成像用于表征前列腺癌患者的疾病范围。
Transl Oncol. 2015 Feb;8(1):25-34. doi: 10.1016/j.tranon.2014.11.005.
8
Whole prostate volume and shape changes with the use of an inflatable and flexible endorectal coil.使用可充气且灵活的直肠内线圈时，整个前列腺的体积和形状会发生变化。
Radiol Res Pract. 2014;2014:903747. doi: 10.1155/2014/903747. Epub 2014 Oct 13.
9
Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.使用磁共振成像对前列腺癌进行肽靶向高分辨率分子成像
Am J Nucl Med Mol Imaging. 2014 Jul 15;4(6):525-36. eCollection 2014.

本文引用的文献

1
Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake.通过抗1-氨基-2-[(18)F]-氟环丁烷-1-羧酸（抗3-[(18)F]FACBC）摄取对原发性前列腺癌进行表征。
Am J Nucl Med Mol Imaging. 2013;3(1):85-96. Epub 2013 Jan 5.
2
Prostate cancer: utility of diffusion-weighted imaging as a marker of side-specific risk of extracapsular extension.前列腺癌：扩散加权成像作为包膜外侵犯侧特异性风险标志物的效用。
J Magn Reson Imaging. 2013 Aug;38(2):312-9. doi: 10.1002/jmri.23972. Epub 2012 Dec 12.
3
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.18F-DCFBC（一种低分子量前列腺特异性膜抗原抑制剂）在转移性前列腺癌患者中的生物分布、肿瘤检测和辐射剂量学。
J Nucl Med. 2012 Dec;53(12):1883-91. doi: 10.2967/jnumed.112.104661.
4
Diffusion-weighted MRI and PSA correlations in patients with prostate cancer treated with radiation and hormonal therapy.放疗和激素治疗前列腺癌患者的弥散加权 MRI 与 PSA 的相关性。
Anticancer Res. 2012 Oct;32(10):4467-71.
5
Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer.传统影像学检查及多参数磁共振成像（MRI、MRS、DWI、MRP）在前列腺癌诊断中的应用
Q J Nucl Med Mol Imaging. 2012 Aug;56(4):331-42.
6
Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.3T 多参数磁共振前列腺外周带癌定位：与组织病理学匹配的无偏癌识别。
Invest Radiol. 2012 Nov;47(11):624-33. doi: 10.1097/RLI.0b013e318263f0fd.
7
Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis.扩散加权 MRI 检测前列腺癌：荟萃分析。
AJR Am J Roentgenol. 2012 Oct;199(4):822-9. doi: 10.2214/AJR.11.7805.
8
Usefulness of diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer.扩散加权磁共振成像在前列腺癌诊断中的应用价值。
Acad Radiol. 2012 Oct;19(10):1215-24. doi: 10.1016/j.acra.2012.05.016.
9
Correlation of magnetic resonance imaging tumor volume with histopathology.磁共振成像肿瘤体积与组织病理学的相关性。
J Urol. 2012 Oct;188(4):1157-1163. doi: 10.1016/j.juro.2012.06.011. Epub 2012 Aug 15.
10
Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T.前列腺癌侵袭性：3T 时磁共振波谱和弥散加权成像的体内评估。
Radiology. 2012 Nov;265(2):457-67. doi: 10.1148/radiol.12111744. Epub 2012 Jul 27.